These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18716412)

  • 21. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW
    Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
    de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
    Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
    Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis.
    Namaka M; Pollitt-Smith M; Gupta A; Klowak M; Vasconcelos M; Turcotte D; Gong Y; Melanson M
    Curr Med Res Opin; 2006 Feb; 22(2):223-39. PubMed ID: 16466595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
    Bartosik-Psujek H; Stelmasiak Z
    Clin Neurol Neurosurg; 2006 Oct; 108(7):644-7. PubMed ID: 16343740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
    Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
    Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of relapsing-remitting multiple sclerosis with interferon beta type 1-b].
    Bencsik K; Rajda C; Klivényi P; Járdánházy T; Török M; Vécsei L
    Orv Hetil; 1999 Apr; 140(14):763-6. PubMed ID: 10224846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interferon-beta response in multiple sclerosis associated with pre-treatment disability].
    Fernandez-Fernandez O; Fernandez-Sanchez VE; Mayorga C; Guerrero-Fernandez M; Leon A; Tamayo-Toledo JA; Alonso A; Romero F; Leyva L; Luque G; de Ramon E
    Rev Neurol; 2006 Sep 16-30; 43(6):322-9. PubMed ID: 16981161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
    Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
    Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
    Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
    Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
    Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA class II and response to interferon-beta in multiple sclerosis.
    Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E
    Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.